Avenue Therapeutics, a pharmaceutical company, has been actively engaging in various license agreements to bolster its product pipeline. The company has secured exclusive rights to IV tramadol for the U.S. market and has made significant payments to Revogenex and Polpharma related to this agreement, including milestone payments upon FDA approval and royalties on net sales. Additionally, Avenue has entered into license agreements with AstraZeneca and Cincinnati Children's Hospital Medical Center for compounds and intellectual property rights related to neurological disorders, with upfront fees and potential milestone and royalty payments. A recent agreement with AnnJi Pharmaceutical Co. Ltd. for AJ201 has led to upfront payments and obligations for future milestone payments and royalties based on net sales. Avenue's financial...Show More

Avenue Therapeutics, a pharmaceutical company, has been actively engaging in various license agreements to bolster its product pipeline. The company has secured exclusive rights to IV tramadol for the U.S. market and has made significant payments to Revogenex and Polpharma related to this agreement, including milestone payments upon FDA approval and royalties on net sales. Additionally, Avenue has entered into license agreements with AstraZeneca and Cincinnati Children's Hospital Medical Center for compounds and intellectual property rights related to neurological disorders, with upfront fees and potential milestone and royalty payments. A recent agreement with AnnJi Pharmaceutical Co. Ltd. for AJ201 has led to upfront payments and obligations for future milestone payments and royalties based on net sales. Avenue's financial commitments include potential payments totaling over $300 million across various development, commercial, and sales-based milestones, as well as royalties on net sales. The company has also engaged in equity transactions, including the issuance of common stock to AnnJi and a registration statement for the resale of shares. Avenue has not reported specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in this announcement. The company's business development efforts are focused on securing and maintaining strategic license agreements to expand its product offerings. Avenue's future plans appear to be centered on advancing its licensed products through clinical trials and towards commercialization, as evidenced by the structured milestone payments and royalty agreements in place with its partners.